coadministered cagrilintide and semaglutide in adults with overweight or obesity the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results CagriSema: a novel dual-pathway approach

Clinical studies have shown that the use of semaglutide leads to a significant reduction in body fat, which is crucial for individuals who are obese or overweight with related conditions such as hypertension, dyslipidemia, or sleep apnea

For those whose goals extend beyond fat loss to overall body sculpting, there are clinician-guided options worth exploring once the fundamentals are in place

Community sources consistently describe improved energy levels and sleep quality as the first noticeable effects, particularly with IV and injectable routes

News There may be a role for semaglutide, but GPs remain key in managing asthma in patients, says a respiratory expert